

Anthony Howell

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5379169/anthony-howell-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

563
papers

41,054
citations

108
h-index

186
g-index

589
ext. papers

45,672
ext. citations

7.4
avg, IF

7.17
L-index

#	Paper	IF	Citations
563	Rare germline copy number variants (CNVs) and breast cancer risk.. <i>Communications Biology</i> , 2022 , 5, 65	6.7	0
562	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. <i>Breast Cancer Research</i> , 2022 , 24, 2	8.3	3
561	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.. <i>JAMA Oncology</i> , 2022 ,	13.4	4
560	The importance of ethnicity: Are breast cancer polygenic risk scores ready for women who are not of White European origin?. <i>International Journal of Cancer</i> , 2022 , 150, 73-79	7.5	1
559	The impact of China's R&D subsidies on R&D investment, technological upgrading and economic growth. <i>Technological Forecasting and Social Change</i> , 2022 , 174, 121212	9.5	8
558	Code of practice needed for samples donated by trial participants.. <i>Lancet Oncology</i> , 2022 , 23, e89-e90	9.7	2
557	Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study.. <i>Breast</i> , 2022 , 64, 47-49	3.6	0
556	Breast cancer risks associated with missense variants in breast cancer susceptibility genes.. <i>Genome Medicine</i> , 2022 , 14, 51	14.4	0
555	The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies. <i>Breast Cancer Research and Treatment</i> , 2021 , 188, 215-223	4.4	2
554	Extended gene panel testing in lobular breast cancer. <i>Familial Cancer</i> , 2021 , 1	3	
553	Extending screening intervals for women at low risk of breast cancer: do they find it acceptable?. <i>BMC Cancer</i> , 2021 , 21, 637	4.8	0
552	Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer. <i>Genetics in Medicine</i> , 2021 , 23, 1969-1976	8.1	1
551	The Relationship between Body Mass Index and Mammographic Density during a Premenopausal Weight Loss Intervention Study. <i>Cancers</i> , 2021 , 13,	6.6	2
550	Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021 ,	1.7	2
549	Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 677-687	4.4	1
548	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 329-337	9.7	14
547	Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. <i>British Journal of Cancer</i> , 2021 , 124, 1373-1378	8.7	1

546	The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. <i>Scientific Reports</i> , 2021 , 11, 2847	4.9	5
545	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021 , 384, 428-439	59.2	143
544	High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer. <i>Journal of Medical Genetics</i> , 2021 ,	5.8	3
543	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021 , 23, 86	8.3	1
542	Gene Panel Testing for Breast Cancer Reveals Differential Effect of Prior Probability. <i>Cancers</i> , 2021 , 13,	6.6	1
541	Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer. <i>Breast</i> , 2021 , 60, 45-52	3.6	4
540	Introducing a low-risk breast screening pathway into the NHS Breast Screening Programme: Views from healthcare professionals who are delivering risk-stratified screening. <i>Women's Health</i> , 2021 , 17, 17455065211009746	3	2
539	Testing a breast cancer prevention and a multiple disease prevention weight loss programme amongst women within the UK NHS breast screening programme-a randomised feasibility study.. <i>Pilot and Feasibility Studies</i> , 2021 , 7, 220	1.9	0
538	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020 , 52, 572-581	36.3	76
537	Picking 'winners' in space: Impact of spatial targeting on firm performance in China. <i>Journal of Regional Science</i> , 2020 , 60, 1025-1046	1.8	2
536	What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). <i>BMC Cancer</i> , 2020 , 20, 570	4.8	16
535	Young adulthood body mass index, adult weight gain and breast cancer risk: the PROCAS Study (United Kingdom). <i>British Journal of Cancer</i> , 2020 , 122, 1552-1561	8.7	7
534	Explaining the urban premium in Chinese cities and the role of place-based policies. <i>Environment and Planning A</i> , 2020 , 52, 1332-1356	2.7	1
533	Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in , and Genes in Women with Very Early-Onset (. <i>Cancers</i> , 2020 , 12,	6.6	11
532	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020 , 11, 312	17.4	20
531	Reply to Comment on "The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial". <i>British Journal of Cancer</i> , 2020 , 122, 925-926	8.7	
530	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020 , 52, 56-73	36.3	56
529	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. <i>Lancet, The</i> , 2020 , 395, 117-122	40	54

528	Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years. <i>Breast Cancer Research</i> , 2020 , 22, 101	8.3	5
527	Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial. <i>Breast</i> , 2020 , 54, 216-221	3.6	1
526	Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders' views on a low-risk breast screening pathway. <i>BMC Cancer</i> , 2020 , 20, 680	4.8	7
525	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020 , 107, 837-848	11	12
524	Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987-2020). <i>Cancers</i> , 2020 , 12,	6.6	2
523	Agglomeration, absorptive capacity and knowledge governance: implications for public-private firm innovation in China. <i>Regional Studies</i> , 2020 , 54, 1069-1083	3.4	10
522	A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. <i>International Journal of Cancer</i> , 2020 , 146, 2122-2129	7.5	19
521	Minimum wage impacts on Han-minority Workers' wage distribution and inequality in urban china. <i>Journal of Urban Economics</i> , 2020 , 115, 103184	4.1	5
520	Industry relatedness, FDI liberalization and the indigenous innovation process in China. <i>Regional Studies</i> , 2020 , 54, 229-243	3.4	17
519	Clustering effects on firm exporting with productivity-enhancing R&D in China. <i>World Economy</i> , 2019 , 42, 3168-3187	1.7	
518	Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention. <i>European Journal of Cancer Prevention</i> , 2019 , 28, 500-506	2	2
517	Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 141-148	4.4	30
516	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019 , 120, 647-657	8.7	28
515	Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer. <i>EClinicalMedicine</i> , 2019 , 7, 39-46	11.3	5
514	The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial. <i>British Journal of Cancer</i> , 2019 , 121, 443-454	8.7	9
513	Heterogeneous impacts of China's economic and development zone program. <i>Journal of Regional Science</i> , 2019 , 59, 797-818	1.8	10
512	Predictors of weight gain in a cohort of premenopausal early breast cancer patients receiving chemotherapy. <i>Breast</i> , 2019 , 45, 1-6	3.6	9
511	Breast cancer risk status influences uptake, retention and efficacy of a weight loss programme amongst breast cancer screening attendees: two randomised controlled feasibility trials. <i>BMC Cancer</i> , 2019 , 19, 1089	4.8	10

510	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019 , 104, 21-34	11	363
509	Ethnic entrepreneurship, initial financing, and business performance in China. <i>Small Business Economics</i> , 2019 , 52, 697-712	5.3	28
508	Intermittent energy restriction for weight loss: Spontaneous reduction of energy intake on unrestricted days. <i>Food Science and Nutrition</i> , 2018 , 6, 674-680	3.2	14
507	Penetrance estimates for , (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?. <i>Journal of Medical Genetics</i> , 2018 , 55, 442-448	5.8	1
506	Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. <i>Annals of Oncology</i> , 2018 , 29, 504-509	10.3	13
505	Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. <i>JAMA Oncology</i> , 2018 , 4, 476-482	13.4	72
504	Psychosocial issues of a population approach to high genetic risk identification: Behavioural, emotional and informed choice issues. <i>Breast</i> , 2018 , 37, 148-153	3.6	11
503	Personalized prevention in high risk individuals: Managing hormones and beyond. <i>Breast</i> , 2018 , 39, 139-147	3.47	15
502	Agglomeration, (un)-related variety and new firm survival in China: Do local subsidies matter?. <i>Papers in Regional Science</i> , 2018 , 97, 485-500	1.8	37
501	Recruitment to the "Breast-Activity and Healthy Eating After Diagnosis" (B-AHEAD) Randomized Controlled Trial. <i>Integrative Cancer Therapies</i> , 2018 , 17, 131-137	3	7
500	White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , 2018 , 168, 326-334	8	15
499	Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. <i>BMC Public Health</i> , 2018 , 18, 178	4.1	9
498	Psychological impact of providing women with personalised 10-year breast cancer risk estimates. <i>British Journal of Cancer</i> , 2018 , 118, 1648-1657	8.7	26
497	The prevention of breast cancer 2018 , 111-128		
496	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018 , 27, 58-66	4	2
495	Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 779-785	4.4	5
494	Innovation and Firm Performance in the People's Republic of China: A Structural Approach with Spillovers. <i>SSRN Electronic Journal</i> , 2018 ,	1	5
493	'For me it's about not feeling like I'm on a diet': a thematic analysis of women's experiences of an intermittent energy restricted diet to reduce breast cancer risk. <i>Journal of Human Nutrition and Dietetics</i> , 2018 , 31, 773-780	3.1	3

492	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 743-750	2.2	51
491	The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study. <i>Journal of Medical Genetics</i> , 2017 , 54, 111-113	5.8	42
490	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. <i>World Development</i> , 2017 , 94, 200-211	5.5	45
489	Picking 'Winners' in China: Do subsidies matter for indigenous innovation and firm productivity?. <i>China Economic Review</i> , 2017 , 44, 154-165	3.9	68
488	Visual assessment of breast density using Visual Analogue Scales: observer variability, reader attributes and reading time 2017 ,		3
487	Marshallian Sources of Relatedness and Their Effects on Firm Survival and Subsequent Success in China. <i>Economic Geography</i> , 2017 , 93, 346-366	3.9	12
486	False-negative MRI breast screening in high-risk women. <i>Clinical Radiology</i> , 2017 , 72, 207-216	2.9	12
485	Clustering Effects on Firm Exporting with Productivity-Enhancing R&D in China. <i>SSRN Electronic Journal</i> , 2017 ,	1	1
484	Identifying the Sources of Agglomeration Benefits within China's Economic and Development Zones. <i>SSRN Electronic Journal</i> , 2017 ,	1	1
483	Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). <i>Journal of Clinical Oncology</i> , 2017 , 35, 2666-2673	2.2	29
482	A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women. <i>European Journal of Radiology</i> , 2017 , 94, 133-139	4.7	7
481	Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores. <i>Familial Cancer</i> , 2017 , 16, 173-179	3	2
480	Potential Benefits and Harms of Intermittent Energy Restriction and Intermittent Fasting Amongst Obese, Overweight and Normal Weight Subjects-A Narrative Review of Human and Animal Evidence. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2017 , 7,	2.3	71
479	Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 591-6	4.4	4
478	Firm R&D, innovation and easing financial constraints in China: Does corporate tax reform matter?. <i>Research Policy</i> , 2016 , 45, 1996-2007	7.5	94
477	Intermittent energy restriction induces changes in breast gene expression and systemic metabolism. <i>Breast Cancer Research</i> , 2016 , 18, 57	8.3	22
476	Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality. <i>Hereditary Cancer in Clinical Practice</i> , 2016 , 14, 8	2.3	25
475	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. <i>Lancet, The</i> , 2016 , 387, 866-73	40	114

474	No strong evidence for increased risk of breast cancer 8-26 years after multiple mammograms in their 30s in females at moderate and high familial risk. <i>British Journal of Radiology</i> , 2016 , 89, 20150960	3.4	2
473	Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 597-601	4.4	19
472	Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 139-43	2.2	22
471	Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. <i>Programme Grants for Applied Research</i> , 2016 , 4, 1-210	1.5	48
470	Mammographic Density Over Time in Women With and Without Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2016 , 291-298	0.9	1
469	Challenges and Opportunities in the Implementation of Risk-Based Screening for Breast Cancer 2016 , 165-187		
468	Should We Adjust Visually Assessed Mammographic Density for Observer Variability?. <i>Lecture Notes in Computer Science</i> , 2016 , 540-547	0.9	
467	Do Marshallian Sources Drive Technological Relatedness? Implications for Firm Survival And Subsequent Success in China. <i>SSRN Electronic Journal</i> , 2016 ,	1	4
466	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. <i>SSRN Electronic Journal</i> , 2016 ,	1	1
465	Marshallian Sources of Relatedness, Technological Capabilities and Firm Productivity in China. <i>SSRN Electronic Journal</i> , 2016 ,	1	5
464	How to Manage the Obese Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4284-4294	2.2	35
463	Breast cancer risk feedback to women in the UK NHS breast screening population. <i>British Journal of Cancer</i> , 2016 , 114, 1045-52	8.7	48
462	Technological relatedness and asymmetrical firm productivity gains under market reforms in China. <i>Cambridge Journal of Regions, Economy and Society</i> , 2016 , rsw024	3.3	10
461	Beliefs about weight and breast cancer: an interview study with high risk women following a 12-month weight loss intervention. <i>Hereditary Cancer in Clinical Practice</i> , 2015 , 13, 1	2.3	21
460	Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. <i>Familial Cancer</i> , 2015 , 14, 531-8	3	34
459	Indigenous innovation with heterogeneous risk and new firm survival in a transitioning Chinese economy. <i>Research Policy</i> , 2015 , 44, 1866-1876	7.5	42
458	A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. <i>European Journal of Cancer</i> , 2015 , 51, 2725-31	7.5	10
457	Can the breast screening appointment be used to provide risk assessment and prevention advice?. <i>Breast Cancer Research</i> , 2015 , 17, 84	8.3	27

456	Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. <i>Breast Cancer Research</i> , 2015 , 17, 147	8.3	124
455	Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. <i>Breast Cancer Research</i> , 2015 , 17, 143	8.3	64
454	Can diet and lifestyle prevent breast cancer: what is the evidence?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , e66-73	7.1	52
453	Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 87-94	4.4	2
452	Local mammographic density as a predictor of breast cancer 2015 ,		2
451	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 2763-70	12.9	29
450	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. <i>Lancet Oncology</i> , 2015 , 16, 67-75	21.7	270
449	Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. <i>Oncotarget</i> , 2015 , 6, 4585-601	3.3	46
448	Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02). <i>Familial Cancer</i> , 2014 , 13, 13-21	3	11
447	MRI breast screening in high-risk women: cancer detection and survival analysis. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 663-72	4.4	105
446	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. <i>Lancet</i> , 2014 , 383, 1041-8	40	428
445	Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. <i>Familial Cancer</i> , 2014 , 13, 189-96	3	19
444	Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. <i>Journal of Medical Genetics</i> , 2014 , 51, 573-80	5.8	14
443	Risk determination and prevention of breast cancer. <i>Breast Cancer Research</i> , 2014 , 16, 446	8.3	180
442	CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 216-27	6.1	131
441	The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. <i>Breast Cancer Research</i> , 2014 , 16, 442	8.3	207
440	JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: connecting fibrosis, inflammation, and stemness for cancer prevention. <i>Cell Cycle</i> , 2014 , 13, 580-99	4.7	42
439	Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. <i>Breast Cancer Research</i> , 2014 , 16, 451	8.3	54

438	Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. <i>British Journal of Cancer</i> , 2014 , 110, 1681-7	8.7	67
437	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1460-1468	21.7	51
436	Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention. <i>Cancer Prevention Research</i> , 2014 , 7, 993-1001	3.2	23
435	Use of Volumetric Breast Density Measures for the Prediction of Weight and Body Mass Index. <i>Lecture Notes in Computer Science</i> , 2014 , 282-289	0.9	1
434	Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives. <i>Breast Cancer Research</i> , 2013 , 15, 401	8.3	1
433	Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 135-42	4.4	119
432	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013 , 15, R92	8.3	248
431	Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. <i>Breast Cancer Research and Treatment</i> , 2013 , 142, 611-8	4.4	45
430	PB.17: Inter-observer agreement in visual analogue scale assessment of percentage breast density. <i>Breast Cancer Research</i> , 2013 , 15,	8.3	2
429	The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. <i>British Journal of Nutrition</i> , 2013 , 110, 1534-47	3.6	229
428	Reverse Warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome?. <i>Seminars in Oncology</i> , 2013 , 40, 403-18	5.5	35
427	Breast cancer prevention: SERMs come of age. <i>Lancet, The</i> , 2013 , 381, 1795-7	4.0	4
426	Creating a tumor-resistant microenvironment: cell-mediated delivery of TNF α completely prevents breast cancer tumor formation in vivo. <i>Cell Cycle</i> , 2013 , 12, 480-90	4.7	23
425	Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 2269-76	4	12
424	Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. <i>Cell Cycle</i> , 2013 , 12, 818-25	4.7	42
423	Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2. <i>Journal of Medical Genetics</i> , 2013 , 50, 368-72	5.8	21
422	Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism: implications for breast cancer prevention. <i>Cell Cycle</i> , 2013 , 12, 289-301	4.7	39
421	Carbonic anhydrase 9 (CA9) and redox signaling in cancer-associated fibroblasts: therapeutic implications. <i>Cell Cycle</i> , 2013 , 12, 2534-5	4.7	2

420	Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancer. <i>Cell Cycle</i> , 2013 , 12, 2935-6	4.7	11
419	Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFB target stromal MCT4. <i>Cell Cycle</i> , 2013 , 12, 2580-97	4.7	65
418	Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. <i>Cell Cycle</i> , 2013 , 12, 172-82	4.7	64
417	Same task, same observers, different values: the problem with visual assessment of breast density 2013 ,		2
416	Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. <i>Cell Cycle</i> , 2012 , 11, 4390-401	4.7	118
415	Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. <i>Cell Cycle</i> , 2012 , 11, 3956-63	4.7	89
414	Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. <i>Antioxidants and Redox Signaling</i> , 2012 , 16, 1264-84	8.4	222
413	Oestrogen and breast cancer: results from the WHI trial. <i>Lancet Oncology, The</i> , 2012 , 13, 437-8	21.7	62
412	Prevention of breast cancer in the context of a national breast screening programme. <i>Journal of Internal Medicine</i> , 2012 , 271, 321-30	10.8	24
411	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. <i>Breast Cancer Research</i> , 2012 , 14, R57	8.3	65
410	Surgical treatment decisions for older patients: The influence of tumour characteristics, patient health and choice. <i>Journal of Geriatric Oncology</i> , 2012 , 3, S19-S20	3.6	
409	Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. <i>Cancer Prevention Research</i> , 2012 , 5, 943-51	3.2	79
408	Metabolic reprogramming of cancer-associated fibroblasts by TGF- β drives tumor growth: connecting TGF- β signaling with "Warburg-like" cancer metabolism and L-lactate production. <i>Cell Cycle</i> , 2012 , 11, 3019-35	4.7	194
407	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. <i>Cancer Treatment Reviews</i> , 2012 , 38, 318-28	14.4	67
406	Energy restriction and the prevention of breast cancer. <i>Proceedings of the Nutrition Society</i> , 2012 , 71, 263-75	2.9	26
405	The milk protein β -casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis. <i>Cell Cycle</i> , 2012 , 11, 3972-82	4.7	23
404	Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. <i>Cell Cycle</i> , 2012 , 11, 1445-54	4.7	139
403	Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. <i>Cell Cycle</i> , 2012 , 11, 4174-80	4.7	88

402	Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1 β autophagy and ketone body production. <i>Cell Cycle</i> , 2012 , 11, 4167-73	4.7	32
401	Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. <i>British Journal of Cancer</i> , 2012 , 107, 230-3	8.7	16
400	Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit. <i>International Journal of Cancer</i> , 2012 , 131, 417-25	7.5	22
399	Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. <i>Cell Cycle</i> , 2012 , 11, 2285-302	4.7	179
398	Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2012 , 7, 423-67	34	216
397	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 727-34	4.4	33
396	Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 625-9	4.4	23
395	Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 1191-8	4.4	32
394	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. <i>Cell Cycle</i> , 2012 , 11, 3599-610	4.7	147
393	Are we ready for online tools in decision making for BRCA1/2 mutation carriers?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 471-3	2.2	8
392	Detection and management of women at increased risk of breast cancer. <i>Clinical Practice (London, England)</i> , 2012 , 9, 391-401	3	
391	Ketone body utilization drives tumor growth and metastasis. <i>Cell Cycle</i> , 2012 , 11, 3964-71	4.7	113
390	Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1 β and HIF2 β in tumor-associated fibroblasts and human breast cancer cells. <i>Cell Cycle</i> , 2012 , 11, 3280-9	4.7	67
389	Metabolic remodeling of the tumor microenvironment: migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. <i>Cell Cycle</i> , 2012 , 11, 3403-14	4.7	37
388	Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. <i>Cell Cycle</i> , 2012 , 11, 2545-56	4.7	95
387	CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. <i>Cell Cycle</i> , 2012 , 11, 2272-84	4.7	96
386	BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. <i>Cell Cycle</i> , 2012 , 11, 4402-13	4.7	64
385	Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: more trouble with phenocopies. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1142-3; author reply 1143-4	2.2	5

384	Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. <i>Cell Cycle</i> , 2012 , 11, 253-63	4.7	55
383	Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole. <i>Clinical Chemistry</i> , 2012 , 58, 782-3	5.5	1
382	Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NF κ B activation in the tumor stroma. <i>Cell Cycle</i> , 2012 , 11, 4152-66	4.7	41
381	Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. <i>Oncotarget</i> , 2012 , 3, 798-810	3.3	90
380	Volumetric and Area-Based Breast Density Measurement in the Predicting Risk of Cancer at Screening (PROCAS) Study. <i>Lecture Notes in Computer Science</i> , 2012 , 228-235	0.9	6
379	Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs "fertilizer". <i>Cell Cycle</i> , 2011 , 10, 2440-9	4.7	165
378	Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. <i>Cancer Biology and Therapy</i> , 2011 , 12, 924-38	4.6	134
377	Migration and Inequality in Xinjiang: A Survey of Han and Uyghur Migrants in Urumqi. <i>Eurasian Geography and Economics</i> , 2011 , 52, 119-139	3.2	69
376	Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. <i>International Journal of Biochemistry and Cell Biology</i> , 2011 , 43, 1045-51	5.6	189
375	Preventive therapy for breast cancer: a consensus statement. <i>Lancet Oncology, The</i> , 2011 , 12, 496-503	21.7	177
374	10-year analysis of the ATAC trial: wrong conclusion? [Authors' reply]. <i>Lancet Oncology, The</i> , 2011 , 12, 217	21.7	2
373	Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. <i>Breast Cancer Research</i> , 2011 , 13, 213	8.3	136
372	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. <i>SSRN Electronic Journal</i> , 2011 ,	1	1
371	Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4266-72	2.2	53
370	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. <i>Growth and Change</i> , 2011 , 42, 200-226	2.3	14
369	Fulvestrant revisited: efficacy and safety of the 500-mg dose. <i>Clinical Breast Cancer</i> , 2011 , 11, 204-10	3	32
368	Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. <i>Cell Cycle</i> , 2011 , 10, 2504-20	4.7	193
367	Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 279-87	4.4	76

366	Hormone replacement therapy and breast cancer. <i>Recent Results in Cancer Research</i> , 2011 , 188, 115-24	1.5	19
365	Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4273-8	2.2	549
364	Cytokine production and inflammation drive autophagy in the tumor microenvironment: role of stromal caveolin-1 as a key regulator. <i>Cell Cycle</i> , 2011 , 10, 1784-93	4.7	103
363	Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. <i>Journal of Medical Genetics</i> , 2011 , 48, 520-2	5.8	59
362	Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. <i>Cancer Biology and Therapy</i> , 2011 , 12, 1101-13	4.6	80
361	Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. <i>Cell Cycle</i> , 2011 , 10, 4047-64	4.7	216
360	Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. <i>Cell Cycle</i> , 2011 , 10, 4065-73	4.7	96
359	Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine. <i>Cell Cycle</i> , 2011 , 10, 2059-63	4.7	56
358	The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. <i>International Journal of Obesity</i> , 2011 , 35, 714-27	5.5	413
357	Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. <i>Cell Cycle</i> , 2011 , 10, 1271-86	4.7	229
356	Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. <i>Cell Cycle</i> , 2011 , 10, 1772-83	4.7	310
355	Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. <i>Cell Cycle</i> , 2011 , 10, 2521-8	4.7	83
354	Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. <i>Cell Cycle</i> , 2011 , 10, 2021-34	4.7	55
353	Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. <i>Cell Cycle</i> , 2011 , 10, 4208-16	4.7	129
352	Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. <i>British Journal of Cancer</i> , 2011 , 105, 22-7	8.7	46
351	Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 744-52	9.7	306
350	Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. <i>Cancer Biology and Therapy</i> , 2011 , 11, 383-94	4.6	100
349	Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. <i>Cancer Biology and Therapy</i> , 2011 , 12, 1085-97	4.6	118

348	Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. <i>Annals of Oncology</i> , 2011 , 22, 857-862	10.3	66
347	Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. <i>British Journal of Cancer</i> , 2010 , 102, 1091-8	8.7	40
346	Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. <i>Cell Cycle</i> , 2010 , 9, 2412-22	4.7	112
345	Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. <i>Cancer Biology and Therapy</i> , 2010 , 10, 537-42	4.6	155
344	Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1829-34	2.2	547
343	Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. <i>Cell Cycle</i> , 2010 , 9, 3506-14	4.7	429
342	HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. <i>Cell Cycle</i> , 2010 , 9, 3534-51	4.7	168
341	Uptake of breast cancer prevention and screening trials. <i>Journal of Medical Genetics</i> , 2010 , 47, 853-5	5.8	15
340	Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. <i>Cell Cycle</i> , 2010 , 9, 2423-33	4.7	208
339	The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. <i>Cell Cycle</i> , 2010 , 9, 4297-306	4.7	134
338	Unerwünschte gynäkologische und operative Interventionen bei der Behandlung des postmenopausalen Mammakarzinoms mit Anastrozol und Tamoxifen. <i>Geburtshilfe Und Frauenheilkunde</i> , 2010 , 70, 57-61	2	
337	Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. <i>Cell Cycle</i> , 2010 , 9, 3256-76	4.7	341
336	Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3411-5	2.2	224
335	Breast cancer susceptibility variants alter risks in familial disease. <i>Journal of Medical Genetics</i> , 2010 , 47, 126-31	5.8	34
334	Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NF κ B activation in the tumor stromal microenvironment. <i>Cell Cycle</i> , 2010 , 9, 3515-33	4.7	321
333	The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. <i>Cell Cycle</i> , 2010 , 9, 3485-505	4.7	215
332	Lung cancer after treatment for breast cancer. <i>Lancet Oncology, The</i> , 2010 , 11, 1184-92	21.7	25
331	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2010 , 11, 1135-41	21.7	671

330	The emerging breast cancer epidemic: early diagnosis and treatment. <i>Breast Cancer Research</i> , 2010 , 12 Suppl 4, S10	8.3	15
329	Significant differences in UK and US female bone density reference ranges. <i>Osteoporosis International</i> , 2010 , 21, 1871-80	5.3	15
328	RASSF1A polymorphism in familial breast cancer. <i>Familial Cancer</i> , 2010 , 9, 263-5	3	15
327	Breast cancer susceptibility variants alter risk in familial ovarian cancer. <i>Familial Cancer</i> , 2010 , 9, 503-6	3	4
326	Can metabolomics in addition to genomics add to prognostic and predictive information in breast cancer?. <i>BMC Medicine</i> , 2010 , 8, 73	11.4	3
325	Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". <i>Aging</i> , 2010 , 2, 185-99	5.6	116
324	Endocrine Therapy 2010 , 329-352		
323	Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2318-24	4	109
322	Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. <i>Journal of Medical Genetics</i> , 2009 , 46, 811-7	5.8	65
321	Normal breast tissue implanted into athymic nude mice identifies biomarkers of the effects of human pregnancy levels of estrogen. <i>Cancer Prevention Research</i> , 2009 , 2, 257-64	3.2	8
320	Biomarkers of dietary energy restriction in women at increased risk of breast cancer. <i>Cancer Prevention Research</i> , 2009 , 2, 720-31	3.2	36
319	A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. <i>American Journal of Obstetrics and Gynecology</i> , 2009 , 200, 80.e1-7	6.4	17
318	Energy restriction for breast cancer prevention. <i>Recent Results in Cancer Research</i> , 2009 , 181, 97-111	1.5	23
317	Breast tumour stroma is a prognostic indicator and target for therapy. <i>Breast Cancer Research</i> , 2009 , 11 Suppl 3, S16	8.3	15
316	Risk reducing mastectomy: outcomes in 10 European centres. <i>Journal of Medical Genetics</i> , 2009 , 46, 254-8	8.8	73
315	Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score [Results from TransATAC. 2009 ,		31
314	Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. <i>BMC Cancer</i> , 2008 , 8, 155	4.8	165
313	The endocrine prevention of breast cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008 , 22, 615-23	6.5	33

312	Should lifestyle modifications be promoted to prevent breast cancer?. <i>Breast Cancer Research</i> , 2008 , 10 Suppl 4, S11	8.3	2
311	The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. <i>Breast Cancer Research</i> , 2008 , 10,	8.3	78
310	Adherence to hormone therapy in a chemoprevention randomised trial. <i>Breast Cancer Research</i> , 2008 , 10,	8.3	78
309	Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. <i>Breast Cancer Research</i> , 2008 , 10, R26	8.3	66
308	Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. <i>Cancer Treatment Reviews</i> , 2008 , 34 Suppl 1, S3-18	14.4	187
307	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2008 , 9, 45-53	21.7	849
306	Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). <i>Lancet Oncology, The</i> , 2008 , 9, 953-61	21.7	101
305	Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1051-7	2.2	312
304	Better life expectancy in women with BRCA2 compared with BRCA1 mutations is attributable to lower frequency and later onset of ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 1535-42	4	14
303	Development of Endocrine Therapy of Breast Cancer 1896 - 2006. <i>Senologie - Zeitschrift Für Mammadiagnostik Und -therapie</i> , 2008 , 5, 50-56	0	
302	The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis. <i>BMC Medical Genomics</i> , 2008 , 1, 42	3.7	95
301	Clinical studies with anastrozole 2008 , 101-125		
300	The origin of estrogen receptor alpha-positive and alpha-negative breast cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 617, 79-86	3.6	1
299	Response and resistance to the endocrine prevention of breast cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 617, 201-11	3.6	10
298	Origins of breast cancer subtypes and therapeutic implications. <i>Nature Clinical Practice Oncology</i> , 2007 , 4, 516-25		126
297	TPD52 and NFKB1 gene expression levels correlate with G2 chromosomal radiosensitivity in lymphocytes of women with and at risk of hereditary breast cancer. <i>International Journal of Radiation Biology</i> , 2007 , 83, 409-20	2.9	12
296	Older women with operable breast cancer are less likely to have surgery. <i>British Journal of Surgery</i> , 2007 , 94, 1209-15	5.3	50
295	Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. <i>International Journal of Cancer</i> , 2007 , 121, 1017-20	7.5	76

294	Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. <i>British Journal of Cancer</i> , 2007 , 96, 1197-203	8.7	90
293	Cyclin-dependent kinase inhibitors and basement membrane interact to regulate breast epithelial cell differentiation and acinar morphogenesis. <i>Cell Proliferation</i> , 2007 , 40, 721-40	7.9	10
292	Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study. <i>Familial Cancer</i> , 2007 , 6, 287-94	3	9
291	Development of Endocrine Therapy of Breast Cancer 1896 - 2006. <i>Geburtshilfe Und Frauenheilkunde</i> , 2007 , 67, 595-601	2	1
290	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. <i>Endocrine-Related Cancer</i> , 2007 , 14, 169-87	5.7	141
289	Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 272-82	9.7	437
288	The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. <i>Growth Hormone and IGF Research</i> , 2007 , 17, 210-9	2	5
287	Breast cancer risk-assessment models. <i>Breast Cancer Research</i> , 2007 , 9, 213	8.3	90
286	Metabolic approaches to breast cancer treatment and prevention. <i>Breast Cancer Research</i> , 2007 , 9,	8.3	1
285	Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 541-541	2.2	2
284	Estrogen deprivation for breast cancer prevention. <i>Recent Results in Cancer Research</i> , 2007 , 174, 151-67	1.5	6
283	Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. <i>Clinical Cancer Research</i> , 2006 , 12, 7025-32	12.9	59
282	Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. <i>Endocrine-Related Cancer</i> , 2006 , 13, 617-28	5.7	62
281	Re: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 643; author reply 643-4	9.7	9
280	Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. <i>Clinical Cancer Research</i> , 2006 , 12, 7033-8	12.9	32
279	Pure oestrogen antagonists for the treatment of advanced breast cancer. <i>Endocrine-Related Cancer</i> , 2006 , 13, 689-706	5.7	87
278	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. <i>Endocrine-Related Cancer</i> , 2006 , 13, 273-8	5.7	111
277	Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. <i>British Journal of Cancer</i> , 2006 , 94, 1021-8	8.7	20

276	Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. <i>British Journal of Cancer</i> , 2006 , 94, 460-4	8.7	51
275	Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial. <i>Breast Cancer Research</i> , 2006 , 8, 1	8.3	1
274	High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. <i>Breast Cancer Research</i> , 2006 , 8, 214	8.3	25
273	Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2006 , 7, 633-43	21.7	295
272	BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. <i>European Journal of Cancer</i> , 2006 , 42, 1143-50	7.5	110
271	Screening younger women with a family history of breast cancer--does early detection improve outcome?. <i>European Journal of Cancer</i> , 2006 , 42, 1385-90	7.5	38
270	The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer. <i>Reviews on Recent Clinical Trials</i> , 2006 , 1, 207-15	1.2	8
269	Energy balance adiposity and breast cancer - energy restriction strategies for breast cancer prevention. <i>Obesity Reviews</i> , 2006 , 7, 33-47	10.6	41
268	Is fulvestrant ("Faslodex") just another selective estrogen receptor modulator?. <i>International Journal of Gynecological Cancer</i> , 2006 , 16 Suppl 2, 521-3	3.5	6
267	Fulvestrant ("Faslodex"): current and future role in breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 57, 265-73	7	39
266	Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 273-84	4.4	191
265	Clinical studies with anastrozole 2006 , 95-118		
264	Automated Breast Tissue Measurement of Women at Increased Risk of Breast Cancer. <i>Lecture Notes in Computer Science</i> , 2006 , 131-136	0.9	15
263	Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. <i>Lancet, The</i> , 2005 , 365, 60-2	40	1805
262	Preventing cancer, cardiovascular disease, and diabetes. <i>Lancet, The</i> , 2005 , 365, 1449-51	40	33
261	Adjuvant aromatase inhibitors for breast cancer. <i>Lancet, The</i> , 2005 , 366, 431-3	40	26
260	ATAC trial update. <i>Lancet, The</i> , 2005 , 365, 1225-1226	40	444
259	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. <i>Lancet Oncology, The</i> , 2005 , 6, 773-9	21.7	71

258	Are aromatase inhibitors superior to antiestrogens?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 93, 237-47	5.1	31
257	Vascular effects of aromatase inhibitors: data from clinical trials. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 95, 143-9	5.1	38
256	The future of fulvestrant ("Faslodex"). <i>Cancer Treatment Reviews</i> , 2005 , 31 Suppl 2, S26-33	14.4	19
255	Clinical development of fulvestrant ("Faslodex"). <i>Cancer Treatment Reviews</i> , 2005 , 31 Suppl 2, S3-9	14.4	22
254	Surgical decisions made by 158 women with hereditary breast cancer aged . <i>European Journal of Surgical Oncology</i> , 2005 , 31, 1112-8	3.6	37
253	A putative human breast stem cell population is enriched for steroid receptor-positive cells. <i>Developmental Biology</i> , 2005 , 277, 443-56	3.1	289
252	New developments in the treatment of postmenopausal breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2005 , 16, 420-8	8.8	21
251	Anastrozole: a new gold standard of hormonal treatment for breast cancer?. <i>Womens Health</i> , 2005 , 1, 309-22	3	2
250	Mechanisms of Disease: prediction and prevention of breast cancer--cellular and molecular interactions. <i>Nature Clinical Practice Oncology</i> , 2005 , 2, 635-46		24
249	Early stopping of clinical trials. <i>Breast Cancer Research</i> , 2005 , 7, 181-3	8.3	6
248	Effects of oestrogen on gene expression in the epithelium and stroma of the normal human breast. <i>Breast Cancer Research</i> , 2005 , 7, 1	8.3	78
247	The future of breast cancer prevention. <i>Breast Cancer Research</i> , 2005 , 7, 1	8.3	78
246	Selective oestrogen receptor modulators, aromatase inhibitors and the female breast. <i>Current Opinion in Obstetrics and Gynecology</i> , 2005 , 17, 429-34	2.4	1
245	O6-(4-bromophenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. <i>British Journal of Cancer</i> , 2005 , 93, 1152-6	8.7	41
244	Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer. <i>Clinical Breast Cancer</i> , 2005 , 6, 302-9	3	10
243	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. <i>Cancer</i> , 2005 , 104, 236-9	6.4	130
242	Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. <i>Breast Cancer Research and Treatment</i> , 2005 , 92, 169-74	4.4	30
241	Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 656-61	4	338

240	Overview of the impact of conventional systemic therapies on breast cancer. <i>Endocrine-Related Cancer</i> , 2005 , 12 Suppl 1, S9-S16	5.7	14
239	Energy balance in patients with advanced NSCLC, metastatic melanoma and metastatic breast cancer receiving chemotherapy--a longitudinal study. <i>British Journal of Cancer</i> , 2005 , 92, 673-80	8.7	37
238	Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 658-658	2.2	11
237	Incorporating Weight Control into Management of Patients with Early Breast Cancer in the U.K.. <i>Nutrition and Disease Prevention</i> , 2005 , 535-560		
236	Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1605-13	2.2	343
235	Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4261-71	2.2	243
234	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. <i>Journal of Medical Genetics</i> , 2004 , 41, 474-80	5.8	189
233	Energy balance in early breast cancer patients receiving adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2004 , 83, 201-10	4.4	96
232	A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 53, 341-8	3.5	20
231	Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. <i>Psycho-Oncology</i> , 2004 , 13, 61-6	3.9	180
230	The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2004 , 18, 47-66	6.5	101
229	Strategies for managing breast cancer risk after the menopause. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2004 , 3, 289-307		3
228	Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?. <i>Breast Cancer Research</i> , 2004 , 6, E7	8.3	17
227	Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. <i>Breast Cancer Research</i> , 2004 , 6, 269-74	8.3	42
226	An early peak of relapse after surgery for breast cancer. <i>Breast Cancer Research</i> , 2004 , 6, 255-7	8.3	5
225	Steroid receptors in human breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2004 , 15, 316-23	8.8	65
224	Spreading the word, but not too thinly. <i>Lancet, The</i> , 2004 , 363, 165-6		40
223	Adjuvant use of anastrozole in breast cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1524-6; author reply 1526-7	2.2	5

222	A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. <i>Breast Cancer Research and Treatment</i> , 2003 , 82, 215-22	4.4	36
221	New approaches to the endocrine prevention and treatment of breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2003 , 52 Suppl 1, S39-44	3.5	26
220	Breast density and breast cancer risk factors in a high-risk population. <i>Breast</i> , 2003 , 12, 10-6	3.6	25
219	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. <i>Cancer</i> , 2003 , 98, 229-38	6.4	271
218	Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. <i>Cancer</i> , 2003 , 98, 1735-44	6.4	755
217	Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. <i>Cancer</i> , 2003 , 98, 1802-10	6.4	660
216	Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. <i>International Journal of Cancer</i> , 2003 , 103, 686-92	7.5	4
215	A roundtable discussion of aromatase inhibitors as therapy for breast cancer. <i>Breast Journal</i> , 2003 , 9, 213-22	1.2	7
214	Regulation of human breast epithelial stem cells. <i>Cell Proliferation</i> , 2003 , 36 Suppl 1, 45-58	7.9	93
213	Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. <i>Journal of Medical Genetics</i> , 2003 , 40, 807-14	5.8	217
212	Do women understand the odds? Risk perceptions and recall of risk information in women with a family history of breast cancer. <i>Public Health Genomics</i> , 2003 , 6, 214-23	1.9	25
211	Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. <i>International Journal of Cancer</i> , 2002 , 101, 555-9	7.5	91
210	Breast cancer: aromatase inhibitors take on tamoxifen. <i>Nature Medicine</i> , 2002 , 8, 1341-4	50.5	28
209	A follow-up study of breast and other cancers in families of an unselected series of breast cancer patients. <i>British Journal of Cancer</i> , 2002 , 86, 718-22	8.7	11
208	Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours. <i>British Journal of Cancer</i> , 2002 , 86, 1797-802	8.7	12
207	Re: risk-reduction mastectomy: clinical issues and research needs. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 307-8	9.7	3
206	Management of women with a family history of breast cancer in the North West Region of England: training for implementing a vision of the future. <i>Journal of Medical Genetics</i> , 2002 , 39, 531-5	5.8	7
205	Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3396-403	2.2	557

204	Fulvestrant (Faslodex): current status in the therapy of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2002 , 2, 151-60	3.5	27
203	First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. <i>Lancet, The</i> , 2002 , 360, 817-24	4.0	611
202	Written report of presented lectures: endocrine treatment and prevention of breast and gynaecological cancers. The scientific basis of endocrine prevention. <i>European Journal of Cancer</i> , 2002 , 38 Suppl 6, S13-4	7.5	14
201	Selective oestrogen receptor downregulator. <i>European Journal of Cancer</i> , 2002 , 38 Suppl 6, S61-2	7.5	3
200	Tamoxifen ("Nolvadex"): a review. <i>Cancer Treatment Reviews</i> , 2002 , 28, 165-80	14.4	171
199	Selective estrogen receptor modulators (SERMs) 2002 , 45-62		
198	Control of Proliferation in the Normal and Neoplastic Breast 2002 , 73-91		
197	Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. <i>Cancer</i> , 2001 , 91, 1191-200	6.4	433
196	High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2001 , 67, 111-6	4.4	194
195	The effects of oestrogens and anti-oestrogens on cognition. <i>Breast</i> , 2001 , 10, 484-91	3.6	31
194	Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. <i>British Journal of Cancer</i> , 2001 , 85, 317-24	8.7	116
193	Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001 , 79, 227-37	5.1	25
192	Uptake of screening and prevention in women at very high risk of breast cancer. <i>Lancet, The</i> , 2001 , 358, 889-90	4.0	48
191	Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1885-92	2.2	203
190	Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. <i>Journal of Medical Genetics</i> , 2001 , 38, 139	5.8	91
189	Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. <i>Clinical Cancer Research</i> , 2001 , 7, 2620-35	12.9	82
188	Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. <i>Cancer Journal (Sudbury, Mass)</i> , 2001 , 7, 377-87	2.2	537
187	Initial results of a study into the effectiveness of breast cancer screening in a population identified to be at high risk. <i>Revue D'epidemiologie Et De Sante Publique</i> , 2001 , 49, 471-5	0.6	6

186	Preliminary experience with pure antiestrogens. <i>Clinical Cancer Research</i> , 2001 , 7, 4369s-4375s; discussion 4411s-4412s	12.9	14
185	Future use of selective estrogen receptor modulators and aromatase inhibitors. <i>Clinical Cancer Research</i> , 2001 , 7, 4402s-4410s; discussion 4411s-4412s	12.9	10
184	ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. <i>Cancer</i> , 2000 , 89, 817-25	6.4	320
183	Clinical follow-up after bilateral risk reducing ('prophylactic') mastectomy: mental health and body image outcomes. <i>Psycho-Oncology</i> , 2000 , 9, 462-72	3.9	103
182	Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity. <i>British Journal of Cancer</i> , 2000 , 82, 354-60	8.7	27
181	Clarification of anastrozole/megestrol acetate trial program design. <i>Journal of Clinical Oncology</i> , 2000 , 18, 4109	2.2	
180	Tamoxifen versus the newer SERMs: what is the evidence?. <i>Annals of Oncology</i> , 2000 , 11 Suppl 3, 255-65	10.3	0
179	Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1329-36	9.7	98
178	A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. <i>European Journal of Surgical Oncology</i> , 2000 , 26, 711-3	3.6	27
177	P27(KIP1) expression indicates that steroid receptor-positive cells are a non-proliferating, differentiated subpopulation of the normal human breast epithelium. <i>European Journal of Cancer</i> , 2000 , 36 Suppl 4, S28-9	7.5	18
176	Faslodex (ICI 182780). an oestrogen receptor downregulator. <i>European Journal of Cancer</i> , 2000 , 36 Suppl 4, S87-8	7.5	68
175	Estrogen Receptor in Mammary Gland Physiology 2000 , 1-16		
174	. <i>Annals of Oncology</i> , 2000 , 11, 255-266	10.3	4
173	ICI 182,780 (Faslodex) 2000 , 89, 817		9
172	Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells. <i>Clinical Cancer Research</i> , 2000 , 6, 966-70	12.9	3
171	The therapeutic potential of novel aromatase inhibitors in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 1999 , 8, 269-79	5.9	4
170	Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 4017-24	5.6	166
169	Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. <i>Journal of Medical Economics</i> , 1999 , 2, 33-43	2.4	8

168	The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. <i>British Journal of Cancer</i> , 1999 , 79, 311-5	8.7	36
167	Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases. <i>British Journal of Cancer</i> , 1999 , 80, 1265-70	8.7	20
166	Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. <i>Breast Cancer Research and Treatment</i> , 1999 , 55, 189-99	4.4	242
165	Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999 , 58, 157-62	4.4	35
164	The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. <i>European Journal of Cancer</i> , 1999 , 35, 47-53	7.5	73
163	Hormonal Resistance in Breast Cancer. <i>Handbook of Experimental Pharmacology</i> , 1999 , 205-221	3.2	1
162	Estrogen responsiveness and control of normal human breast proliferation. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1998 , 3, 23-35	2.4	133
161	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. <i>Cancer</i> , 1998 , 83, 1142-1152	6.4	292
160	Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. <i>Psycho-Oncology</i> , 1998 , 7, 402-12	3.9	89
159	Effect of early American results on patients in a tamoxifen prevention trial (IBIS). International Breast Cancer Intervention Study. <i>Lancet, The</i> , 1998 , 352, 1222	4.0	8
158	The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors alone. <i>Cancer Treatment Reviews</i> , 1998 , 24, 173-84	14.4	4
157	Screening by mammography, women with a family history of breast cancer. <i>European Journal of Cancer</i> , 1998 , 34, 937-40	7.5	74
156	Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. <i>American Journal of Clinical Nutrition</i> , 1998 , 68, 1431S-1435S	7	166
155	A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1?) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy. <i>Blood</i> , 1998 , 92, 1532-1540	2.2	23
154	The primary use of endocrine therapies. <i>Recent Results in Cancer Research</i> , 1998 , 152, 227-44	1.5	9
153	A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1?) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy. <i>Blood</i> , 1998 , 92, 1532-1540	2.2	
152	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma 1998 , 83, 1142		193
151	Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. <i>Cancer</i> , 1998 , 83, 1142-52	6.4	66

150	Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 1059-65	9.7	39
149	Oestrogens, Beatson and endocrine therapy. <i>Endocrine-Related Cancer</i> , 1997 , 4, 371-380	5.7	11
148	Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 118-22	5.6	68
147	ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997 , 61, 145-149	5.1	16
146	Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. <i>European Journal of Cancer</i> , 1997 , 33, 2183-93	7.5	50
145	Review of recent trials of chemotherapy for advanced breast cancer: studies excluding taxanes. <i>European Journal of Cancer</i> , 1997 , 33, 2171-82	7.5	11
144	Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone. <i>British Journal of Cancer</i> , 1997 , 75, 251-7	8.7	80
143	Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer. <i>Breast</i> , 1997 , 6, 186-189	3.6	25
142	Changes in the normal human breast throughout the menstrual cycle: relevance to breast carcinogenesis. <i>Endocrine-Related Cancer</i> , 1997 , 4, 23-33	5.7	16
141	Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. <i>Breast Cancer Research and Treatment</i> , 1997 , 45, 121-33	4.4	225
140	Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. <i>International Journal of Cancer</i> , 1997 , 72, 608-13	7.5	82
139	Investigation of mammary epithelial cell-bone marrow stroma interactions using primary human cell culture as a model of metastasis. <i>International Journal of Cancer</i> , 1997 , 73, 690-6	7.5	17
138	Recent advances in endocrine therapy of breast cancer. <i>BMJ: British Medical Journal</i> , 1997 , 315, 863-6		35
137	Dissociation between steroid receptor expression and cell proliferation in the human breast. <i>Cancer Research</i> , 1997 , 57, 4987-91	10.1	444
136	Carcinomatous meningitis in solid tumours. <i>Annals of Oncology</i> , 1996 , 7, 773-86	10.3	70
135	A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. <i>European Journal of Cancer</i> , 1996 , 32A, 404-12	7.5	222
134	New endocrine therapies for breast cancer. <i>European Journal of Cancer</i> , 1996 , 32A, 576-88	7.5	63
133	Cancer genetics clinics. <i>European Journal of Cancer</i> , 1996 , 32A, 391-2	7.5	20

132	Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. <i>Journal of Clinical Oncology</i> , 1996 , 14, 2000-11	2.2	320
131	Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer. <i>Annals of Oncology</i> , 1996 , 7, 1051-7	10.3	7
130	Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. <i>British Journal of Cancer</i> , 1996 , 74, 300-8	8.7	153
129	Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. <i>Breast Cancer Research and Treatment</i> , 1996 , 41, 31-41	4.4	37
128	New endocrine treatments for breast cancer: biological and clinical aspects. <i>Breast</i> , 1996 , 5, 170-174	3.6	4
127	Models of new antioestrogen action in vivo: primary tumours. <i>Breast</i> , 1996 , 5, 186-191	3.6	5
126	Clinical studies with the specific pure antiestrogen ICI 182780. <i>Breast</i> , 1996 , 5, 192-195	3.6	1
125	Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. <i>Journal of Pathology</i> , 1996 , 180, 44-9	9.4	40
124	Entry into the tamoxifen prevention trial depends on women's estimates of the population risk of breast cancer. <i>Breast</i> , 1995 , 4, 203-204	3.6	2
123	Should I Take HRT, Doctor? Hormone Replacement Therapy in Women at Increased Risk of Breast Cancer and in Survivors of the Disease. <i>The Journal of the British Menopause Society</i> , 1995 , 1, 9-17		2
122	The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. <i>Endocrinology</i> , 1995 , 136, 164-71	4.8	150
121	Oestrogen sulphotransferases in malignant and normal human breast tissue. <i>Endocrine-Related Cancer</i> , 1995 , 2, 227-233	5.7	24
120	A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. <i>European Journal of Cancer</i> , 1995 , 31A, 137-42	7.5	82
119	Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. <i>Lancet, The</i> , 1995 , 345, 989-90	40	27
118	Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. <i>Lancet, The</i> , 1995 , 345, 29-30	40	268
117	Clues to the mechanisms of endocrine resistance from clinical studies in advanced breast cancer. <i>Endocrine-Related Cancer</i> , 1995 , 2, 131-139	5.7	7
116	Allelic imbalance on chromosome 1 in human breast cancer. II. Microsatellite repeat analysis. <i>Genes Chromosomes and Cancer</i> , 1995 , 12, 24-31	5	49
115	Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. <i>Annals of Oncology</i> , 1994 , 5, 217-224	10.3	13

114	Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. <i>Cancer</i> , 1994 , 74, 3135-41	6.4	93
113	Phenotypic heterogeneity in breast fibroblasts: functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. <i>International Journal of Cancer</i> , 1994 , 59, 25-32	7.5	42
112	Tamoxifen withdrawal responses enhance observations or clinical clues to antioestrogen resistance?. <i>Breast</i> , 1994 , 3, 199-201	3.6	6
111	Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. <i>British Journal of Cancer</i> , 1994 , 70, 169-72	8.7	43
110	Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. <i>British Journal of Cancer</i> , 1994 , 70, 204-11	8.7	67
109	The impact of genetic counselling on risk perception in women with a family history of breast cancer. <i>British Journal of Cancer</i> , 1994 , 70, 934-8	8.7	155
108	Cancer experience in the relatives of an unselected series of breast cancer patients. <i>British Journal of Cancer</i> , 1994 , 70, 102-11	8.7	28
107	Rapid haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cells (PBPC) as sole source of support collected at a single apheresis. <i>Bone Marrow Transplantation</i> , 1994 , 13, 839-40	4.4	5
106	Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. <i>Cancer Research</i> , 1994 , 54, 408-14	10.1	200
105	Familial breast cancer. <i>BMJ: British Medical Journal</i> , 1994 , 308, 183-7		61
104	Cyclical Activity and Ageing of the Human Breast: Clues to Assessment of Risk and Strategies for Prevention 1994 , 27-46		4
103	Fetal-like fibroblasts: their production of migration-stimulating factor and role in tumor progression. <i>Cancer Treatment and Research</i> , 1994 , 71, 277-98	3.5	10
102	Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. <i>European Journal of Cancer</i> , 1993 , 29A, 1141-5	7.5	137
101	Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants. <i>Lancet, The</i> , 1993 , 341, 369	4.0	69
100	Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. <i>European Journal of Cancer</i> , 1993 , 29A, 209-17	7.5	26
99	Perception of risk in women with a family history of breast cancer. <i>British Journal of Cancer</i> , 1993 , 67, 612-4	8.7	147
98	Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. <i>British Journal of Cancer</i> , 1993 , 67, 606-11	8.7	92
97	High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer. <i>British Journal of Cancer</i> , 1993 , 67, 825-9	8.7	30

96	A linkage study in seven breast cancer families. <i>American Journal of Human Genetics</i> , 1993 , 52, 786-8	11	5
95	Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. <i>Postgraduate Medical Journal</i> , 1992 , 68, 434-9	2	21
94	Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. <i>Annals of Oncology</i> , 1992 , 3, 611-7	10.3	128
93	Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. <i>European Journal of Cancer</i> , 1992 , 28A, 1023-8	7.5	57
92	Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. <i>Journal of Pathology</i> , 1992 , 167, 25-32	9.4	108
91	Normal human breast xenografts activate N-nitrosodimethylamine: identification of potential target cells for an environmental nitrosamine. <i>British Journal of Cancer</i> , 1992 , 66, 79-83	8.7	7
90	Changes in the extracellular matrix of the normal human breast during the menstrual cycle. <i>Cell and Tissue Research</i> , 1992 , 268, 167-77	4.2	75
89	Prognostic relevance of serum hyaluronan levels in patients with breast cancer. <i>International Journal of Cancer</i> , 1992 , 52, 873-6	7.5	20
88	The Contribution of Perturbed Epithelial-Mesenchymal Interactions to Cancer Pathogenesis 1992 , 61-72		
87	Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. <i>British Journal of Cancer</i> , 1991 , 64, 353-6	8.7	218
86	Objective measurement of therapeutic response in breast cancer using tumour markers. <i>British Journal of Cancer</i> , 1991 , 64, 757-63	8.7	53
85	Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. <i>International Journal of Cancer</i> , 1991 , 48, 206-10	7.5	107
84	Prospective assessment of the role of five tumour markers in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1991 , 33, 403-10	7.4	33
83	The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. <i>Calcified Tissue International</i> , 1991 , 49, 433-5	3.9	46
82	Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. <i>British Journal of Cancer</i> , 1991 , 64, 349-52	8.7	152
81	Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 1629-33		34
80	Migration stimulating activity in serum of breast cancer patients. <i>Lancet, The</i> , 1991 , 337, 130-3	40	26
79	Heterogeneity amongst fibroblasts in the production of migration stimulating factor (MSF): implications for cancer pathogenesis. <i>Exs</i> , 1991 , 59, 127-46		10

78	The Systemic Treatment of Bone Metastases 1991 , 121-147		5
77	Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. <i>British Journal of Cancer</i> , 1990 , 61, 123-5	8.7	24
76	C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. <i>British Journal of Cancer</i> , 1990 , 61, 39-45	8.7	64
75	Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. <i>Differentiation</i> , 1990 , 42, 199-207	3.5	57
74	Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1990 , 25, 435-9	3.5	19
73	New endocrine approaches to breast cancer. <i>Baillieres Clinical Endocrinology and Metabolism</i> , 1990 , 4, 67-84		6
72	Assessment of four monoclonal antibodies as serum markers in breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1990 , 26, 1127-32		20
71	Growth factor-assisted chemotherapy--the Manchester experience. <i>Novartis Foundation Symposium</i> , 1990 , 148, 201-10; discussion 211-4		2
70	Tamoxifen as an Agonist for Metastatic Breast Cancer 1990 , 49-58		8
69	Extended role for needle biopsy in the management of carcinoma of the breast. <i>British Journal of Surgery</i> , 1989 , 76, 553-8	5.3	15
68	Epidermal and transforming growth factor alpha in patients with breast tumours. <i>British Journal of Cancer</i> , 1989 , 59, 605-9	8.7	53
67	The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. <i>British Journal of Cancer</i> , 1989 , 60, 121-5	8.7	239
66	West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. I. Patients with involved axillary lymph nodes. <i>British Journal of Cancer</i> , 1989 , 60, 911-8	8.7	24
65	The expression of milk fat globule antigens within human mammary tumours: relationship to steroid hormone receptors and response to endocrine treatment. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 459-67		10
64	Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 1719-25		9
63	The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 9499-503	11.5	267
62	Clinical evidence for the involvement of oestrogen in the development and progression of breast cancer. <i>Proceedings of the Royal Society of Edinburgh Section B Biological Sciences</i> , 1989 , 95, 49-57		3
61	Expression of differentiation antigens within human mammary tumours is related to response to endocrine therapy and survival. <i>International Journal of Cancer</i> , 1988 , 42, 154-8	7.5	8

60	The effect of age and menstrual cycle upon proliferative activity of the normal human breast. <i>British Journal of Cancer</i> , 1988 , 58, 163-70	8.7	261
59	Bisphosphonates and bone metastases. <i>British Journal of Cancer</i> , 1988 , 58, 556-7	8.7	14
58	The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast. <i>British Journal of Cancer</i> , 1988 , 58, 631-4	8.7	25
57	In situ hybridisation and S1 mapping show that the presence of infiltrating plasma cells is associated with poor prognosis in breast cancer. <i>British Journal of Cancer</i> , 1988 , 58, 715-22	8.7	11
56	Cellular aspects of breast cancer: workshop report. <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 21-8		2
55	The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 1567-72		84
54	Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. <i>BMJ: British Medical Journal</i> , 1988 , 297, 772-3		72
53	Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy. <i>British Medical Journal</i> , 1988 , 296, 811-4		48
52	The Possible Role of Abnormal Fibroblasts in the Pathogenesis of Breast Cancer 1988 , 142-157		3
51	Hypothesis: persistent expression of fetal phenotypic characteristics by fibroblasts is associated with an increased susceptibility to neoplastic disease. <i>Pathobiology</i> , 1987 , 55, 11-7	3.6	15
50	DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast. <i>British Journal of Cancer</i> , 1987 , 55, 553-9	8.7	63
49	Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 979-82		31
48	Fibroblasts from relatives of patients with hereditary breast cancer show fetal-like behaviour in vitro. <i>Lancet, The</i> , 1987 , 1, 1455-7	4.0	50
47	cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment. <i>British Journal of Cancer</i> , 1987 , 56, 763-73	8.7	19
46	Endocrine therapy for advanced carcinoma of the breast: effect of tumor heterogeneity and site of biopsy on the predictive value of progesterone receptor estimations. <i>Cancer Research</i> , 1987 , 47, 296-9	10.1	11
45	Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. <i>Cancer Research</i> , 1987 , 47, 300-4	10.1	52
44	Occurrence of a fetal fibroblast phenotype in familial breast cancer. <i>International Journal of Cancer</i> , 1986 , 37, 831-6	7.5	56
43	Molecular expression of epitopes recognized by monoclonal antibodies HMFG-1 and HMFG-2 in human breast cancers: diversity, variability and relationship to prognostic factors. <i>International Journal of Cancer</i> , 1986 , 38, 89-96	7.5	21

42	A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response. <i>British Journal of Urology</i> , 1986 , 58, 534-8		15
41	Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy. <i>British Journal of Urology</i> , 1986 , 58, 539-44		18
40	Tumour information from needle biopsy. <i>Lancet, The</i> , 1986 , 2, 1342-3	40	
39	Mechanism of action of adjuvant chemotherapy in early breast cancer. <i>Lancet, The</i> , 1986 , 2, 411-4	40	76
38	A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. <i>Journal of Clinical Oncology</i> , 1986 , 4, 1326-30	2.2	134
37	Systemic Treatment and Survival in Carcinoma of the Breast 1986 , 303-312		
36	Retroperitoneal tumour infiltration detected by bone scanning in patients with infiltrating lobular carcinoma of the breast. <i>British Journal of Surgery</i> , 1985 , 72, 626-8	5.3	4
35	Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. <i>British Medical Journal</i> , 1985 , 290, 185-7		49
34	Carcinomatous meningitis associated with infiltrating lobular carcinoma of the breast. <i>European Journal of Surgical Oncology</i> , 1985 , 11, 33-6	3.6	27
33	Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone. <i>British Medical Journal</i> , 1984 , 289, 831		
32	A comparison of three assays used for the in vitro chemosensitivity testing of human tumours. <i>British Journal of Cancer</i> , 1984 , 49, 57-63	8.7	26
31	The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. <i>International Journal of Cancer</i> , 1984 , 33, 299-304	7.5	99
30	Dibromodulcitol, mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1984 , 20, 873-6		6
29	Steroid-hormone receptors and survival after first relapse in breast cancer. <i>Lancet, The</i> , 1984 , 1, 588-91	40	149
28	Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. <i>Lancet, The</i> , 1984 , 2, 307-11	40	56
27	A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. <i>British Journal of Cancer</i> , 1984 , 50, 23-30	8.7	277
26	Twenty-four hour combination chemotherapy: a feasibility study with implications for improved adjuvant treatment of breast cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1983 , 19, 1-4		10
25	Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. <i>Lancet, The</i> , 1983 , 2, 415-9	40	52

24	Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. <i>Lancet, The</i> , 1983 , 1, 839-43	40	51
23	Variation of receptor status in cancer of the breast. <i>British Journal of Cancer</i> , 1983 , 47, 511-5	8.7	23
22	The clinical value of immunohistochemically demonstrable CEA in breast cancer: a possible method of selecting patients for adjuvant chemotherapy. <i>British Journal of Cancer</i> , 1982 , 46, 757-64	8.7	22
21	Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1982 , 8, 281-4	3.5	22
20	Serum proteins as tumour markers for breast cancer. <i>British Journal of Cancer</i> , 1981 , 43, 542-5	8.7	8
19	Effect of Altitude on Water Excretion. <i>Clinical Science</i> , 1980 , 59, 11P-11P	6.5	
18	Effect of sodium butyrate on synthesis of specific proteins by human breast-carcinoma cells. <i>British Journal of Cancer</i> , 1980 , 42, 616-9	8.7	5
17	Histological detection of oestrogen receptor in human breast carcinomas. <i>Lancet, The</i> , 1980 , 1, 171-3	40	56
16	Tumour markers in breast cancer. <i>British Journal of Cancer</i> , 1979 , 40, 710-8	8.7	29
15	The synthesis of the glycoprotein hormone alpha subunit by human breast carcinomas. <i>European Journal of Cancer</i> , 1979 , 15, 693-702		13
14	The Use of Milk-Protein Estimation to Assess the Effect of Hormones on Human Breast in Organ Culture. <i>Clinical Science</i> , 1979 , 56, 22P-22P	6.5	
13	An Automated Test for Antigen-Antibody Complexes in Human Sera with a Low-Affinity Igm Antiserum. <i>Clinical Science</i> , 1979 , 56, 30P-31P	6.5	
12	Predictive classification of human breast carcinomas based on lactalbumin synthesis. <i>Lancet, The</i> , 1977 , 2, 14-6	40	22
11	Release of colony-stimulating activity from the isolated perfused rat liver. <i>Clinical Science and Molecular Medicine</i> , 1976 , 50, 539-44		1
10	The effects of drugs that cause neutropenia upon colony formation by bone marrow cells in semi-solid agar. <i>Clinical Science and Molecular Medicine</i> , 1974 , 46, 619-28		8
9	Urban Agglomeration, Selection and the Impact of Policy Distortions on Firm Productivity in China. <i>SSRN Electronic Journal</i> ,	1	3
8	A Structural Model of Indigenous Innovation and Catch-Up for Developing Economies. <i>SSRN Electronic Journal</i> ,	1	1
7	Minimum Wage Impacts on Inequality, Job Formality and the Ethnic Wage Gap in Urban China. <i>SSRN Electronic Journal</i> ,	1	2

6	Ethnicity, Start-Up Finance, and Entrepreneurship in China. <i>SSRN Electronic Journal</i> ,	1	1
5	Direct and Spillover Effects of Targeted Cash Transfers on Ethnic Rural-Urban Migration in China. <i>SSRN Electronic Journal</i> ,	1	1
4	Inter-Industry Relatedness, Absorptive Capacity and Firm Productivity in a Transitioning Chinese Economy. <i>SSRN Electronic Journal</i> ,	1	2
3	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1
2	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2
1	Picking Winner in China: Do Subsidies Matter for Indigenous Innovation and Firm Productivity?. <i>SSRN Electronic Journal</i> ,	1	1